Metabolic activation of ftorafur [R,S-1-(tetrahydro-2-furanyl)-5-fluorouracil]: the microsomal oxidative pathway.

Suppr

超能文献

作者信息

El Sayed Y M, Sadée W

出版信息

Biochem Pharmacol. 1982 Sep 15;31(18):3006-8. doi: 10.1016/0006-2952(82)90279-9.

DOI:10.1016/0006-2952(82)90279-9

PMID:6814451

Abstract

摘要

相似文献

Metabolic activation of ftorafur [R,S-1-(tetrahydro-2-furanyl)-5-fluorouracil]: the microsomal oxidative pathway.

Biochem Pharmacol. 1982 Sep 15;31(18):3006-8. doi: 10.1016/0006-2952(82)90279-9.

Metabolic activation of R,S-1-(tetrahydro-2-furanyl)-5-fluorouracil (ftorafur) to 5-fluorouracil by soluble enzymes.R,S-1-(四氢-2-呋喃基)-5-氟尿嘧啶（替加氟）通过可溶性酶代谢活化为5-氟尿嘧啶。

Cancer Res. 1983 Sep;43(9):4039-44.

Cytochrome P-450-dependent oxidative cleavage of 1-(tetrahydro-2-furanyl)-5-fluorouracil to 5-fluorouracil.

Jpn J Pharmacol. 1984 Sep;36(1):43-9. doi: 10.1254/jjp.36.43.

Activation of Ftorafue [R,S-1-(tetrahydro-2-furanyl)-5-fluorouracil] to 5-fluorouracil and gamma-butyrolactone.

Cancer Res. 1980 Aug;40(8 Pt 1):2814-9.

Stereoselective metabolism of ftorafur (R,S-1-(tetrahydro-2-furanyl)-5-fluorouracil).呋喃氟尿嘧啶（R,S-1-(四氢-2-呋喃基)-5-氟尿嘧啶）的立体选择性代谢

Cancer Chemother Pharmacol. 1981;7(1):55-9. doi: 10.1007/BF00258214.

The pharmacology of ftorafur (R, S-1-(tetrahydro-2-furanyl)-5-fluorouracil.呋氟尿嘧啶（R，S-1-（四氢-2-呋喃基）-5-氟尿嘧啶）的药理学

Recent Results Cancer Res. 1981;76:100-14. doi: 10.1007/978-3-642-81565-2_9.

Disposition and metabolism of 1-(tetrahydro-2-furanyl)-5-fluorouracil (ftorafur) in humans.

Cancer Res. 1978 Nov;38(11 Pt 1):3867-70.

Identification of metabolites of 1-(tetrahydro-2-furanyl)-5-fluorouracil (FT-207) formed in vitro by rat liver microsomes.

Chem Pharm Bull (Tokyo). 1980 Jun;28(6):1795-80. doi: 10.1248/cpb.28.1795.

Enzymatic formation of 5-fluorouracil from 1-(tetrahydro-2-furanyl)- 5-fluorouracil (tegafur) in human tumor tissues.人肿瘤组织中1-(四氢-2-呋喃基)-5-氟尿嘧啶（替加氟）酶促形成5-氟尿嘧啶。

Chem Pharm Bull (Tokyo). 1981 May;29(5):1486-8. doi: 10.1248/cpb.29.1486.

Bioactivation of tegafur to 5-fluorouracil is catalyzed by cytochrome P-450 2A6 in human liver microsomes in vitro.在体外人肝微粒体中，替加氟向5-氟尿嘧啶的生物活化由细胞色素P-450 2A6催化。

Clin Cancer Res. 2000 Nov;6(11):4409-15.

引用本文的文献

The optimal neoadjuvant treatment of locally advanced esophageal cancer.局部晚期食管癌的最佳新辅助治疗

J Thorac Dis. 2019 Apr;11(Suppl 5):S621-S631. doi: 10.21037/jtd.2018.11.143.

Phase II Study of the Triple Combination Chemotherapy of SOXIRI (S-1/Oxaliplatin/Irinotecan) in Patients with Unresectable Pancreatic Ductal Adenocarcinoma.SOXIRI（替吉奥/奥沙利铂/伊立替康）三联化疗治疗不可切除胰腺导管腺癌的 II 期研究。

Oncologist. 2019 Jun;24(6):749-e224. doi: 10.1634/theoncologist.2018-0900. Epub 2019 Jan 24.

CYP2A6 Polymorphisms Associate with Outcomes of S-1 Plus Oxaliplatin Chemotherapy in Chinese Gastric Cancer Patients.CYP2A6基因多态性与中国胃癌患者S-1联合奥沙利铂化疗的疗效相关。

Genomics Proteomics Bioinformatics. 2017 Aug;15(4):255-262. doi: 10.1016/j.gpb.2016.11.004. Epub 2017 Aug 12.

Fluoropyrimidine-Based Chemotherapy as First-Line Treatment for Advanced Gastric Cancer: a Bayesian Network Meta-Analysis.基于氟嘧啶的化疗作为晚期胃癌的一线治疗：一项贝叶斯网络荟萃分析。

Pathol Oncol Res. 2016 Oct;22(4):853-61. doi: 10.1007/s12253-016-0078-1. Epub 2016 May 28.

Enantioselectivity in the cytochrome P450-dependent conversion of tegafur to 5-fluorouracil in human liver microsomes.在手性细胞色素 P450 依赖性转化替加氟为 5-氟尿嘧啶过程中，人肝微粒体的立体选择性。

Pharmacol Res Perspect. 2013 Oct;1(1):e00009. doi: 10.1002/prp2.9. Epub 2013 Oct 23.

Dose-finding study on adjuvant chemotherapy with S-1 plus oxaliplatin for gastric cancer.S-1联合奥沙利铂用于胃癌辅助化疗的剂量探索性研究。

Mol Clin Oncol. 2014 Jan;2(1):93-98. doi: 10.3892/mco.2013.191. Epub 2013 Sep 23.

Clinical development of S-1 for non-small cell lung cancer: a Japanese perspective.S-1 治疗非小细胞肺癌的临床开发：日本视角。

Ther Adv Med Oncol. 2013 Sep;5(5):301-11. doi: 10.1177/1758834013500702.

Tegafur/gimeracil/oteracil (S-1) approved for the treatment of advanced gastric cancer in adults when given in combination with cisplatin: a review comparing it with other fluoropyrimidine-based therapies.替吉奥（S-1）与顺铂联合用于治疗成人晚期胃癌时已获批准：与其他基于氟嘧啶的疗法的比较综述。

Onco Targets Ther. 2011;4:193-201. doi: 10.2147/OTT.S19059. Epub 2011 Nov 15.

Phase II study of UFT with leucovorin and irinotecan (TEGAFIRI): first-line therapy for metastatic colorectal cancer.优福定联合亚叶酸钙和伊立替康（TEGAFIRI）的II期研究：转移性结直肠癌的一线治疗

Br J Cancer. 2007 Aug 6;97(3):297-301. doi: 10.1038/sj.bjc.6603889. Epub 2007 Jul 17.

The tegafur-based dihydropyrimidine dehydrogenase inhibitory fluoropyrimidines, UFT/leucovorin (ORZEL) and S-1: a review of their clinical development and therapeutic potential.基于替加氟的二氢嘧啶脱氢酶抑制性氟嘧啶类药物，优福定/亚叶酸钙（ORZEL）和S-1：临床开发与治疗潜力综述

Invest New Drugs. 2000 Nov;18(4):331-42. doi: 10.1023/a:1006445214741.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验